Aktuellt
SENASTE
Redeye provides a comment on Scandinavian ChemoTech's recently announced collaboration with a global operator of equine hospitals. The initial transaction is valued at approximately EUR45k, with the customer expected to "gradually integrate TSE into its treatment offerings." The fair value range is maintained but further derisked.
LÄS MER
